Pulmonary aspergillosis: A clinical update

QJM: An International Journal of Medicine

Volumn 100, Issue 6, 2007, Pages 317-334

  Zmeili, O S ^a   Soubani, A O ^a,b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HARPER UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CARBAMAZEPINE; CASPOFUNGIN; CORTICOSTEROID; CYCLOSPORIN; CYCLOSPORIN A; ECHINOCANDIN; FUNGUS ANTIGEN; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOMODULATING AGENT; ITRACONAZOLE; MICAFUNGIN; PLACEBO; POSACONAZOLE; PREDNISONE; PYRROLE DERIVATIVE; QUINIDINE; RIFAMPICIN; SULFONYLUREA; TERFENADINE; TUMOR NECROSIS FACTOR ANTIBODY; UNINDEXED DRUG; VORICONAZOLE; WARFARIN;

ASPERGILLUS; BLURRED VISION; BRONCHOPULMONARY ASPERGILLOMA; CHRONIC LUNG DISEASE; CLINICAL FEATURE; CLINICAL PROTOCOL; CLINICAL TRIAL; COLOR VISION; DIAGNOSTIC PROCEDURE; DISEASE SEVERITY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; ELECTROLYTE DISTURBANCE; HUMAN; IMMUNE STATUS; IMMUNE SYSTEM; IMMUNOCOMPROMISED PATIENT; LIVER FUNCTION TEST; LOW DRUG DOSE; LUNG ASPERGILLOSIS; NEPHROTOXICITY; NON INVASIVE MEASUREMENT; NONHUMAN; PHOTOPHOBIA; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; RISK FACTOR; SIDE EFFECT; SKIN MANIFESTATION; VISUAL DISORDER;

EID: 34447561921     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hcm035     Document Type: Review

References (199)

1. Soubani AO, Chandrasekar PH. The clinical spectrum of pulmonary aspergillosis. Chest 2002; 121:1988-99.
2. Rankin NE. Disseminated aspergillosis and moniliasis associated with agranulocytosis and antibiotic therapy. Br Med J 1953; 1 918-19.
3. Chamilos G, Luna M, Lewis RE, et al. Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003). Haematologica 2006; 91:986-9.
4. Groll AH, Shah PM, Mentzel C, Schneider M, Just-Nuebling G, Huebner K. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect 1996; 33:23-32.
5. Yeghen T, Kibbler CC, Prentice HG, et al. Management of invasive pulmonary aspergillosis in hematology patients: A review of 87 consecutive cases at a single institution. Clin Infect Dis 2000; 31:859-68.
6. Fukuda T, Boeckh M, Carter RA, et al. Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. Blood 2003; 102:827-33.
7. Gerson SL, Talbot GH, Hurwitz S, Strom BL, Lusk EJ, Cassileth PA. Prolonged granulocytopenia: The major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia. Ann Intern Med 1984; 100:345-51.
8. Segal BH, Walsh TJ. Current approaches to diagnosis and treatment of invasive aspergillosis. Am J Respir Crit Care Med 2006; 173 707-17.
9. Soubani AO, Miller KB, Hassoun PM. Pulmonary complications of bone marrow transplantation. Chest 1996; 109:1066-77.
10. Kotloff RM, Ahya VN, Crawford SW. Pulmonary complications of solid organ and hematopoietic stem cell transplantation. Am J Respir Crit Care Med 2004; 170:22-48.
11. Morgan J, Wannemuehler KA, Marr KA, et al. Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: Interim results of a prospective multicenter surveillance program. Med Mycol 2005; 43(Suppl. 1):S49-58.
12. Wald A, Leisenring W, van Burik JA, Bowden RA. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis 1997; 175:1459-66.
13. Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: Changes in epidemiology and risk factors. Blood 2002; 100:4358-66.
14. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34:909-17.
15. Baddley JW, Stroud TP, Salzman D, Pappas PG. Invasive mold infections in allogeneic bone marrow transplant recipients. Clin Infect Dis 2001; 32:1319-24.
16. Junghanss C, Marr KA, Carter RA, et al. Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: A matched control study. Biol Blood Marrow Transplant 2002; 8 512-20.
17. Warris A, Bjorneklett A, Gaustad P. Invasive pulmonary aspergillosis associated with infliximab therapy. N Engl J Med 2001; 344 1099-100.
18. Cordonnier C, Ribaud P, Herbrecht R, et al. Prognostic factors for death due to invasive aspergillosis after hematopoietic stem cell transplantation: A 1-year retrospective study of consecutive patients at French transplantation centers. Clin Infect Dis 2006; 42 955-63.
19. Ribaud P, Chastang C, Latge JP, et al. Survival and prognostic factors of invasive aspergillosis after allogeneic bone marrow transplantation. Clin Infect Dis 1999; 28:322-30.
20. Nichols WG, Corey L, Gooley T, Davis C, Boeckh M. High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: Evidence for indirect effects of primary CMV infection. J Infect Dis 2002; 185:273-82.
21. Segal BH, Barnhart LA, Anderson VL, Walsh TJ, Malech HL, Holland SM. Posaconazole as salvage therapy in patients with chronic granulomatous disease and invasive filamentous fungal infection. Clin Infect Dis 2005; 40:1684-8.
22. Libanore M, Prini E, Mazzetti M, et al. Invasive Aspergillosis in Italian AIDS patients. Infection 2002; 30:341-5.
23. Denning DW, Follansbee SE, Scolaro M, Norris S, Edelstein H, Stevens DA. Pulmonary aspergillosis in the acquired immunodeficiency syndrome. N Engl J Med 1991; 324:654-62.
24. Lortholary O, Meyohas MC, Dupont B, et al. Invasive aspergillosis in patients with acquired immunodeficiency syndrome: Report of 33 cases. French Cooperative Study Group on Aspergillosis in AIDS. Am J Med 1993; 95:177-87.
25. Mylonakis E, Barlam TF, Flanigan T, Rich JD. Pulmonary aspergillosis and invasive disease in AIDS: Review of 342 cases. Chest 1998; 114 251-62.
26. Kemper CA, Hostetler JS, Follansbee SE, et al. Ulcerative and plaque-like tracheobronchitis due to infection with Aspergillus in patients with AIDS. Clin Infect Dis 1993; 17:344-52.
27. Wallace JM, Lim R, Browdy BL, et al. Risk factors and outcomes associated with identification of Aspergillus in respiratory specimens from persons with HIV disease. Pulmonary Complications of HIV Infection Study Group. Chest 1998; 114:131-7.
28. Ader F, Nseir S, Le Berre R, et al. Invasive pulmonary aspergillosis in chronic obstructive pulmonary disease: An emerging fungal pathogen. Clin Microbiol Infect 2005; 11:427-9.
29. Carrascosa Porras M, Herreras Martinez R, Corral Mones J, Ares Ares M, Zabaleta Murguiondo M, Ruchel R. Fatal Aspergillus myocarditis following short-term corticosteroid therapy for chronic obstructive pulmonary disease. Scand J Infect Dis 2002; 34:224-7.
30. Bulpa PA, Dive AM, Garrino MG, et al. Chronic obstructive pulmonary disease patients with invasive pulmonary aspergillosis: benefits of intensive care? Intensive Care Med 2001; 27 59-67.
31. Vandewoude KH, Blot SI, Depuydt P, et al. Clinical relevance of Aspergillus isolation from respiratory tract samples in critically ill patients. Crit Care 2006; 10:R31.
32. Dimopoulos G, Piagnerelli M, Berre J, Eddafali B, Salmon I, Vincent JL. Disseminated aspergillosis in intensive care unit patients: An autopsy study. J Chemother 2003; 15:71-5.
33. Vandewoude KH, Blot SI, Benoit D, Colardyn F, Vogelaers D. Invasive aspergillosis in critically ill patients: Attributable mortality and excesses in length of ICU stay and ventilator dependence. J Hosp Infect 2004; 56:269-76.
34. Meersseman W, Vandecasteele SJ, Wilmer A, Verbeken E, Peetermans WE, Van Wijngaerden E. Invasive aspergillosis in critically ill patients without malignancy. Am J Respir Crit Care Med 2004; 170:621-5.
35. Janssen JJ, Strack van Schijndel RJ, van der Poest Clement EH, Ossenkoppele GJ, Thijs LG, Huijgens PC. Outcome of ICU treatment in invasive aspergillosis. Intensive Care Med 1996; 22:1315-22.
36. Garnacho-Montero J, Amaya-Villar R, Ortiz-Leyba C, et al. Isolation of Aspergillus spp. from the respiratory tract in critically ill patients: Risk factors, clinical presentation and outcome. Crit Care 2005; 9:R191-9.
37. Garnacho-Montero J, Amaya-Villar R. A validated clinical approach for the management of aspergillosis in critically ill patients: Ready, steady, go! Crit Care 2006; 10:132.
38. Khasawneh F, Mohamad T, Moughrabieh MK, Lai Z, Ager J, Soubani AO. Isolation of Aspergillus in critically ill patients: A potential marker of poor outcome. J Crit Care 2006; 21:322-7.
39. Iwen PC, Rupp ME, Langnas AN, Reed EC, Hinrichs SH. Invasive pulmonary aspergillosis due to Aspergillus terreus: 12-year experience and review of the literature. Clin Infect Dis 1998; 26:1092-7.
40. Young RC, Bennett JE, Vogel CL, Carbone PP, DeVita VT. Aspergillosis. The spectrum of the disease in 98 patients. Medicine (Baltimore) 1970; 49:147-73.
41. Prystowsky SD, Vogelstein B, Ettinger DS, et al. Invasive aspergillosis. N Engl J Med 1976; 295:655-8.
42. Allo MD, Miller J, Townsend T, Tan C. Primary cutaneous aspergillosis associated with Hickman intravenous catheters. N Engl J Med 1987; 317:1105-8.
43. Albelda SM, Talbot GH, Gerson SL, Miller WT, Cassileth PA. Pulmonary cavitation and massive hemoptysis in invasive pulmonary aspergillosis. Influence of bone marrow recovery in patients with acute leukemia. Am Rev Respir Dis 1985; 131:115-20.
44. Judson MA, Sahn SA. Endobronchial lesions in HIV-infected individuals. Chest 1994; 105:1314-23.
45. Nathan SD, Shorr AF, Schmidt ME, Burton NA. Aspergillus and endobronchial abnormalities in lung transplant recipients. Chest 2000; 118:403-7.
46. Denning DW. Invasive aspergillosis. Clin Infect Dis 1998; 26 781-803.
47. Ruhnke M, Bohme A, Buchheidt D, et al. Diagnosis of invasive fungal infections in hematology and oncology-guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2003; 82(Suppl. 2):S141-8.
48. Soubani AO, Khanchandani G, Ahmed HP. Clinical significance of lower respiratory tract Aspergillus culture in elderly hospitalized patients. Eur J Clin Microbiol Infect Dis 2004; 23:491-4.
49. Nalesnik MA, Myerowitz RL, Jenkins R, Lenkey J, Herbert D. Significance of Aspergillus species isolated from respiratory secretions in the diagnosis of invasive pulmonary aspergillosis. J Clin Microbiol 1980; 11:370-6.
50. Horvath JA, Dummer S. The use of respiratory-tract cultures in the diagnosis of invasive pulmonary aspergillosis. Am J Med 1996; 100:171-8.
51. Treger TR, Visscher DW, Bartlett MS, Smith JW. Diagnosis of pulmonary infection caused by Aspergillus: Usefulness of respiratory cultures. J Infect Dis 1985; 152:572-6.
52. Soubani AO, Qureshi MA. Invasive pulmonary aspergillosis following bone marrow transplantation: Risk factors and diagnostic aspect. Haematologia 2002; 32:427-37.
53. Yu VL, Muder RR, Poorsattar A. Significance of isolation of Aspergillus from the respiratory tract in diagnosis of invasive pulmonary aspergillosis. Results from a three-year prospective study. Am J Med 1986; 81:249-54.
54. Tang CM, Cohen J. Diagnosing fungal infections in immunocompromised hosts. J Clin Pathol 1992; 45:1-5.
55. Duthie R, Denning DW. Aspergillus fungemia: Report of two cases and review. Clin Infect Dis 1995; 20:598-605.
56. Libshitz HI, Pagani JJ. Aspergillosis and mucormycosis: Two types of opportunistic fungal pneumonia. Radiology 1981; 140:301-6.
57. Kuhlman JE, Fishman EK, Siegelman SS. Invasive pulmonary aspergillosis in acute leukemia: Characteristic findings on CT, the CT halo sign, and the role of CT in early diagnosis. Radiology 1985; 157 611-14.
58. Caillot D, Casasnovas O, Bernard A, et al. Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J Clin Oncol 1997; 15:139-47.
59. Caillot D, Mannone L, Cuisenier B, Couaillier JF. Role of early diagnosis and aggressive surgery in the management of invasive pulmonary aspergillosis in neutropenic patients. Clin Microbiol Infect 2001; 7(Suppl. 2):54-61.
60. Kuhlman JE, Fishman EK, Burch PA, Karp JE, Zerhouni EA, Siegelman SS. Invasive pulmonary aspergillosis in acute leukemia. The contribution of CT to early diagnosis and aggressive management. Chest 1987; 92 95-9.
61. Curtis AM, Smith GJ, Ravin CE. Air crescent sign of invasive aspergillosis. Radiology 1979; 133:17-21.
62. Gaeta M, Blandino A, Scribano E, Minutoli F, Volta S, Pandolfo I. Computed tomography halo sign in pulmonary nodules: Frequency and diagnostic value. J Thorac Imaging 1999; 14:109-13.
63. Greene R. The radiological spectrum of pulmonary aspergillosis. Med Mycol 2005; 43(Suppl. 1):S147-54.
64. Heussel CP, Kauczor HU, Heussel GE, et al. Pneumonia in febrile neutropenic patients and in bone marrow and blood stem-cell transplant recipients: Use of high-resolution computed tomography. J Clin Oncol 1999; 17:796-805.
65. Horger M, Hebart H, Einsele H, et al. Initial CT manifestations of invasive pulmonary aspergillosis in 45 non-HIV immunocompromised patients: Association with patient outcome? Eur J Radiol 2005; 55:437-44.
66. Albelda SM, Talbot GH, Gerson SL, Miller WT, Cassileth PA. Role of fiberoptic bronchoscopy in the diagnosis of invasive pulmonary aspergillosis in patients with acute leukemia. Am J Med 1984; 76:1027-34.
67. Kahn FW, Jones JM, England DM. The role of bronchoalveolar lavage in the diagnosis of invasive pulmonary aspergillosis. Am J Clin Pathol 1986; 86:518-23.
68. Levy H, Horak DA, Tegtmeier BR, Yokota SB, Forman SJ. The value of bronchoalveolar lavage and bronchial washings in the diagnosis of invasive pulmonary aspergillosis. Respir Med 1992; 86:243-8.
69. Reichenberger F, Habicht J, Matt P, et al. Diagnostic yield of bronchoscopy in histologically proven invasive pulmonary aspergillosis. Bone Marrow Transplant 1999; 24:1195-9.
70. Maschmeyer G, Beinert T, Buchheidt D, et al. Diagnosis and antimicrobial therapy of pulmonary infiltrates in febrile neutropenic patients-guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2003; 82(Suppl. 2):S118-26.
71. Panackal AA, Marr KA. Scedosporium/Pseudallescheria infections. Semin Respir Crit Care Med 2004; 25:171-81.
72. Walsh TJ, Groll AH. Overview: Non-fumigatus species of Aspergillus: perspectives on emerging pathogens in immunocompromised hosts. Curr Opin Investig Drugs 2001; 2:1366-7.
73. Lass-Florl C, Griff K, Mayr A, et al. Epidemiology and outcome of infections due to Aspergillus terreus: 10-year single centre experience. Br J Haematol 2005; 131:201-7.
74. Steinbach WJ, Benjamin DK, Jr., Kontoyiannis DP, et al. Infections due to Aspergillus terreus: A multicenter retrospective analysis of 83 cases. Clin Infect Dis 2004; 39:192-8.
75. Hachem RY, Kontoyiannis DP, Boktour MR, et al. Aspergillus terreus: An emerging amphotericin B-resistant opportunistic mold in patients with hematologic malignancies. Cancer 2004; 101 1594-600.
76. Kontoyiannis DP, Lewis RE, May GS, Osherov N, Rinaldi MG. Aspergillus nidulans is frequently resistant to amphotericin B. Mycoses 2002; 45:406-7.
77. Walsh TJ, Raad I, Patterson TF, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: An externally controlled trial. Clin Infect Dis 2007; 44:2-12.
78. Boutboul F, Alberti C, Leblanc T, et al. Invasive aspergillosis in allogeneic stem cell transplant recipients: Increasing antigenemia is associated with progressive disease. Clin Infect Dis 2002; 34 939-43.
79. Marr KA, Balajee SA, McLaughlin L, Tabouret M, Bentsen C, Walsh TJ. Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: Variables that affect performance. J Infect Dis 2004; 190:641-9.
80. Pfeiffer CD, Fine JP, Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: A meta-analysis. Clin Infect Dis 2006; 42:1417-27.
81. Herbrecht R, Letscher-Bru V, Oprea C, et al. Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients. J Clin Oncol 2002; 20:1898-906.
82. Singh N, Obman A, Husain S, Aspinall S, Mietzner S, Stout JE. Reactivity of platelia Aspergillus galactomannan antigen with piperacillin-tazobactam: Clinical implications based on achievable concentrations in serum. Antimicrob Agents Chemother 2004; 48 1989-92.
83. Marr KA, Laverdiere M, Gugel A, Leisenring W. Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. Clin Infect Dis 2005; 40:1762-9.
84. Ansorg R, van den Boom R, Rath PM. Detection of Aspergillus galactomannan antigen in foods and antibiotics. Mycoses 1997; 40:353-7.
85. Busca A, Locatelli F, Barbui A, et al. Usefulness of sequential Aspergillus galactomannan antigen detection combined with early radiologic evaluation for diagnosis of invasive pulmonary aspergillosis in patients undergoing allogeneic stem cell transplantation. Transplant Proc 2006; 38:1610-13.
86. Musher B, Fredricks D, Leisenring W, Balajee SA, Smith C, Marr KA. Aspergillus galactomannan enzyme immunoassay and quantitative PCR for diagnosis of invasive aspergillosis with bronchoalveolar lavage fluid. J Clin Microbiol 2004; 42:5517-22.
87. Klont RR, Mennink-Kersten MA, Verweij PE. Utility of Aspergillus antigen detection in specimens other than serum specimens. Clin Infect Dis 2004; 39:1467-74.
88. Salonen J, Lehtonen OP, Terasjarvi MR, Nikoskelainen J. Aspergillus antigen in serum, urine and bronchoalveolar lavage specimens of neutropenic patients in relation to clinical outcome. Scand J Infect Dis 2000; 32:485-90.
89. Hizel K, Kokturk N, Kalkanci A, Ozturk C, Kustimur S, Tufan M. Polymerase chain reaction in the diagnosis of invasive aspergillosis. Mycoses 2004; 47:338-42.
90. Buchheidt D, Baust C, Skladny H, et al. Detection of Aspergillus species in blood and bronchoalveolar lavage samples from immunocompromised patients by means of 2-step polymerase chain reaction: clinical results. Clin Infect Dis 2001; 33:428-35.
91. Loeffler J, Kloepfer K, Hebart H, et al. Polymerase chain reaction detection of aspergillus DNA in experimental models of invasive aspergillosis. J Infect Dis 2002; 185:1203-6.
92. Halliday C, Hoile R, Sorrell T, et al. Role of prospective screening of blood for invasive aspergillosis by polymerase chain reaction in febrile neutropenic recipients of haematopoietic stem cell transplants and patients with acute leukaemia. Br J Haematol 2006; 132:478-86.
93. Obayashi T, Yoshida M, Mori T, et al. Plasma (1-43)-beta-D-glucan measurement in diagnosis of invasive deep mycosis and fungal febrile episodes. Lancet 1995; 345:17-20.
94. Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus. Clin Infect Dis 2002; 34:7-14.
95. Johnson LB, Kauffman CA. Voriconazole: A new triazole antifungal agent. Clin Infect Dis 2003; 36:630-7.
96. Sambatakou H, Dupont B, Lode H, Denning DW. Voriconazole treatment for subacute invasive and chronic pulmonary aspergillosis. Am J Med 2006; 119:527.e17-24.
97. Ghannoum MA, Kuhn DM. Voriconazole - better chances for patients with invasive mycoses. Eur J Med Res 2002; 7:242-56.
98. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347:408-15.
99. Pitisuttithum P, Negroni R, Graybill JR, et al. Activity of posaconazole in the treatment of central nervous system fungal infections. J Antimicrob Chemother 2005; 56:745-55.
100. Spanakis EK, Aperis G, Mylonakis E. New agents for the treatment of fungal infections: Clinical efficacy and gaps in coverage. Clin Infect Dis 2006; 43:1060-8.
101. Cohen-Wolkowiez M, Benjamin DK, Jr., Steinbach WJ, Smith PB. Anidulafungin: A new echinocandin for the treatment of fungal infections. Drugs Today (Barc) 2006; 42:533-44.
102. Aliff TB, Maslak PG, Jurcic JG, et al. Refractory Aspergillus pneumonia in patients with acute leukemia: Successful therapy with combination caspofungin and liposomal amphotericin. Cancer 2003; 97:1025-32.
103. Kontoyiannis DP, Hachem R, Lewis RE, et al. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer 2003; 98:292-9.
104. Graybill JR, Bocanegra R, Gonzalez GM, Najvar LK. Combination antifungal therapy of murine aspergillosis: Liposomal amphotericin B and micafungin. J Antimicrob Chemother 2003; 52:656-62.
105. Marr KA, Boeckh M, Carter RA, Kim HW, Corey L. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 2004; 39 797-802.
106. Perea S, Gonzalez G, Fothergill AW, Kirkpatrick WR, Rinaldi MG, Patterson TF. In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp. Antimicrob Agents Chemother 2002; 46:3039-41.
107. Denning DW, Marr KA, Lau WM, et al. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect 2006; 53:337-49.
108. Klont RR, Mennink-Kersten MA, Ruegebrink D, et al. Paradoxical increase in circulating Aspergillus antigen during treatment with caspofungin in a patient with pulmonary aspergillosis. Clin Infect Dis 2006; 43:e23-5.
109. Moreau P, Zahar JR, Milpied N, et al. Localized invasive pulmonary aspergillosis in patients with neutropenia. Effectiveness of surgical resection. Cancer 1993; 72:3223-6.
110. Reichenberger F, Habicht J, Kaim A, et al. Lung resection for invasive pulmonary aspergillosis in neutropenic patients with hematologic diseases. Am J Respir Crit Care Med 1998; 158 885-90.
111. Habicht JM, Reichenberger F, Gratwohl A, Zerkowski HR, Tamm M. Surgical aspects of resection for suspected invasive pulmonary fungal infection in neutropenic patients. Ann Thorac Surg 1999; 68:321-5.
112. Pidhorecky I, Urschel J, Anderson T. Resection of invasive pulmonary aspergillosis in immunocompromised patients. Ann Surg Oncol 2000; 7:312-17.
113. Matt P, Bernet F, Habicht J, et al. Predicting outcome after lung resection for invasive pulmonary aspergillosis in patients with neutropenia. Chest 2004; 126:1783-8.
114. Baron O, Guillaume B, Moreau P, et al. Aggressive surgical management in localized pulmonary mycotic and nonmycotic infections for neutropenic patients with acute leukemia: Report of eighteen cases. J Thorac Cardiovasc Surg 1998; 115:63-8.
115. Giles FJ. Monocyte-macrophages, granulocyte-macrophage colony-stimulating factor, and prolonged survival among patients with acute myeloid leukemia and stem cell transplants. Clin Infect Dis 1998; 26:1282-9.
116. Roilides E, Holmes A, Blake C, Venzon D, Pizzo PA, Walsh TJ. Antifungal activity of elutriated human monocytes against Aspergillus fumigatus hyphae: Enhancement by granulocyte-macrophage colony-stimulating factor and interferon-gamma. J Infect Dis 1994; 170:894-9.
117. Roilides E, Sein T, Holmes A, et al. Effects of macrophage colony-stimulating factor on antifungal activity of mononuclear phagocytes against Aspergillus fumigatus. J Infect Dis 1995; 172:1028-34.
118. Rowe JM, Andersen JW, Mazza JJ, et al. A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (455 to 70 years of age) with acute myelogenous leukemia: A study of the Eastern Cooperative Oncology Group (E1490). Blood 1995; 86:457-62.
119. Ozer H, Armitage JO, Bennett CL, et al. 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol 2000; 18:3558-85.
120. Roilides E, Uhlig K, Venzon D, Pizzo PA, Walsh TJ. Prevention of corticosteroid-induced suppression of human polymorphonuclear leukocyte-induced damage of Aspergillus fumigatus hyphae by granulocyte colony-stimulating factor and gamma interferon. Infect Immun 1993; 61:4870-7.
121. Nagai H, Guo J, Choi H, Kurup V. Interferon-gamma and tumor necrosis factor-alpha protect mice from invasive aspergillosis. J Infect Dis 1995; 172:1554-60.
122. A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. The International Chronic Granulomatous Disease Cooperative Study Group. N Engl J Med 1991; 324:509-16.
123. Safdar A. Strategies to enhance immune function in hematopoietic transplantation recipients who have fungal infections. Bone Marrow Transplant 2006; 38:327-37.
124. Safdar A, Rodriguez G, Ohmagari N, et al. The safety of interferon-gamma-1b therapy for invasive fungal infections after hematopoietic stem cell transplantation. Cancer 2005; 103 731-9.
125. Price TH, Bowden RA, Boeckh M, et al. Phase I/II trial of neutrophil transfusions from donors stimulated with G-CSF and dexamethasone for treatment of patients with infections in hematopoietic stem cell transplantation. Blood 2000; 95:3302-9.
126. Sherertz RJ, Belani A, Kramer BS, et al. Impact of air filtration on nosocomial Aspergillus infections. Unique risk of bone marrow transplant recipients. Am J Med 1987; 83:709-18.
127. Mattiuzzi GN, Kantarjian H, O'Brien S, et al. Intravenous itraconazole for prophylaxis of systemic fungal infections in patients with acute myelogenous leukemia and high-risk myelodysplastic syndrome undergoing induction chemotherapy. Cancer 2004; 100:568-73.
128. Ullmann AJ, Cornely OA. Antifungal prophylaxis for invasive mycoses in high risk patients. Curr Opin Infect Dis 2006; 19:571-6.
129. Gefter WB, Weingrad TR, Epstein DM, Ochs RH, Miller WT. "Semi-invasive" pulmonary aspergillosis: A new look at the spectrum of aspergillus infections of the lung. Radiology 1981; 140 313-21.
130. Binder RE, Faling LJ, Pugatch RD, Mahasaen C, Snider GL. Chronic necrotizing pulmonary aspergillosis: A discrete clinical entity. Medicine (Baltimore) 1982; 61:109-24.
131. Saraceno JL, Phelps DT, Ferro TJ, Futerfas R, Schwartz DB. Chronic necrotizing pulmonary aspergillosis: Approach to management. Chest 1997; 112:541-8.
132. Grahame-Clarke CN, Roberts CM, Empey DW. Chronic necrotizing pulmonary aspergillosis and pulmonary phycomycosis in cystic fibrosis. Respir Med 1994; 88:465-8.
133. Denning DW. Chronic forms of pulmonary aspergillosis. Clin Microbiol Infect 2001; 7(Suppl. 2):25-31.
134. Kim SY, Lee KS, Han J, et al. Semiinvasive pulmonary aspergillosis: CT and pathologic findings in six patients. AJR Am J Roentgenol 2000; 174:795-8.
135. Parra I, Remacha A, Rezusta A, et al. Chronic necrotizing pulmonary aspergillosis. Med Mycol 2004; 42:369-71.
136. Denning DW, Riniotis K, Dobrashian R, Sambatakou H. Chronic cavitary and fibrosing pulmonary and pleural aspergillosis: Case series, proposed nomenclature change, and review. Clin Infect Dis 2003; 37(Suppl. 3):S265-80.
137. Caras WE, Pluss JL. Chronic necrotizing pulmonary aspergillosis: pathologic outcome after itraconazole therapy. Mayo Clin Proc 1996; 71:25-30.
138. Kauffman CA. Quandary about treatment of aspergillomas persists. Lancet 1996; 347:1640.
139. Zizzo G, Castriota-Scanderbeg A, Zarrelli N, Nardella G, Daly J, Cammisa M. Pulmonary aspergillosis complicating ankylosing spondylitis. Radiol Med 1996; 91:817-8.
140. Kawamura S, Maesaki S, Tomono K, Tashiro T, Kohno S. Clinical evaluation of 61 patients with pulmonary aspergilloma. Intern Med 2000; 39 209-12.
141. Aspergilloma and residual tuberculous cavities - the results of a resurvey. Tubercle 1970; 51:227-45.
142. Rosenheim SH, Schwarz J. Cavitary pulmonary cryptococcosis complicated by aspergilloma. Am Rev Respir Dis 1975; 111:549-53.
143. Sarosi GA, Silberfarb PM, Saliba NA, Huggin PM, Tosh FE. Aspergillomas occurring in blastomycotic cavities. Am Rev Respir Dis 1971; 104:581-4.
144. Tomee JF, van der Werf TS, Latge JP, Koeter GH, Dubois AE, Kauffman HF. Serologic monitoring of disease and treatment in a patient with pulmonary aspergilloma. Am J Respir Crit Care Med 1995; 151 199-204.
145. Rafferty P, Biggs BA, Crompton GK, Grant IW. What happens to patients with pulmonary aspergilloma? Analysis of 23 cases. Thorax 1983; 38:579-83.
146. Gefter WB. The spectrum of pulmonary aspergillosis. J Thorac Imaging 1992; 7:56-74.
147. Faulkner SL, Vernon R, Brown PP, Fisher RD, Bender HW, Jr. Hemoptysis and pulmonary aspergilloma: Operative versus nonoperative treatment. Ann Thorac Surg 1978; 25:389-92.
148. Addrizzo-Harris DJ, Harkin TJ, McGuinness G, Naidich DP, Rom WN. Pulmonary aspergilloma and AIDS. A comparison of HIV-infected and HIV-negative individuals. Chest 1997; 111:612-18.
149. Aslam PA, Eastridge CE, Hughes FA Jr. Aspergillosis of the lung-an eighteen-year experience. Chest 1971; 59:28-32.
150. Garvey J, Crastnopol P, Weisz D, Khan F. The surgical treatment of pulmonary aspergillomas. J Thorac Cardiovasc Surg 1977; 74 542-7.
151. Daly RC, Pairolero PC, Piehler JM, Trastek VF, Payne WS, Bernatz PE. Pulmonary aspergilloma. Results of surgical treatment. J Thorac Cardiovasc Surg 1986; 92:981-8.
152. Karas A, Hankins JR, Attar S, Miller JE, McLaughlin JS. Pulmonary aspergillosis: An analysis of 41 patients. Ann Thorac Surg 1976; 22:1-7.
153. Jewkes J, Kay PH, Paneth M, Citron KM. Pulmonary aspergilloma: Analysis of prognosis in relation to haemoptysis and survey of treatment. Thorax 1983; 38:572-8.
154. Glimp RA, Bayer AS. Pulmonary aspergilloma. Diagnostic and therapeutic considerations. Arch Intern Med 1983; 143:303-8.
155. Stevens DA, Kan VL, Judson MA, et al. Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America. Clin Infect Dis 2000; 30:696-709.
156. Tuncel E. Pulmonary air meniscus sign. Respiration 1984; 46 139-44.
157. Roberts CM, Citron KM, Strickland B. Intrathoracic aspergilloma: Role of CT in diagnosis and treatment. Radiology 1987; 165:123-8.
158. Bandoh S, Fujita J, Fukunaga Y, et al. Cavitary lung cancer with an aspergilloma-like shadow. Lung Cancer 1999; 26:195-8.
159. Le Thi Huong D, Wechsler B, Chamuzeau JP, Bisson A, Godeau P. Pulmonary aspergilloma complicating Wegener's granulomatosis. Scand J Rheumatol 1995; 24:260.
160. McCarthy DS, Pepys J. Pulmonary aspergilloma-clinical immunology. Clin Allergy 1973; 3:57-70.
161. Judson MA. Noninvasive Aspergillus pulmonary disease. Semin Respir Crit Care Med 2004; 25:203-19.
162. Andrews CP, Weiner MH. Aspergillus antigen detection in bronchoalveolar lavage fluid from patients with invasive aspergillosis and aspergillomas. Am J Med 1982; 73:372-80.
163. Yamada H, Kohno S, Koga H, Maesaki S, Kaku M. Topical treatment of pulmonary aspergilloma by antifungals. Relationship between duration of the disease and efficacy of therapy. Chest 1993; 103:1421-5.
164. Munk PL, Vellet AD, Rankin RN, Muller NL, Ahmad D. Intracavitary aspergilloma: Transthoracic percutaneous injection of amphotericin gelatin solution. Radiology 1993; 188:821-3.
165. Lee KS, Kim HT, Kim YH, Choe KO. Treatment of hemoptysis in patients with cavitary aspergilloma of the lung: Value of percutaneous instillation of amphotericin B. AJR Am J Roentgenol 1993; 161 727-31.
166. Klein JS, Fang K, Chang MC. Percutaneous transcatheter treatment of an intracavitary aspergilloma. Cardiovasc Intervent Radiol 1993; 16:321-4.
167. Hammerman KJ, Sarosi GA, Tosh FE. Amphotericin B in the treatment of saprophytic forms of pulmonary aspergillosis. Am Rev Respir Dis 1974; 109:57-62.
168. Campbell JH, Winter JH, Richardson MD, Shankland GS, Banham SW. Treatment of pulmonary aspergilloma with itraconazole. Thorax 1991; 46:839-41.
169. Dupont B. Itraconazole therapy in aspergillosis: Study in 49 patients. J Am Acad Dermatol 1990; 23:607-14.
170. Impens N, De Greve J, De Beule K, Meysman M, De Beuckelaere S, Schandevyl W. Oral treatment with itraconazole of aspergilloma in cavitary lung cancer. Eur Respir J 1990; 3:837-9.
171. Tsubura E. [Multicenter clinical trial of itraconazole in the treatment of pulmonary aspergilloma. Pulmonary Aspergilloma Study Group]. Kekkaku 1997; 72:557-64 (Abstract).
172. Soltanzadeh H, Wychulis AR, Sadr F, Bolanowski PJ, Neville WE. Surgical treatment of pulmonary aspergilloma. Ann Surg 1977; 186 13-16.
173. Massard G, Roeslin N, Wihlm JM, Dumont P, Witz JP, Morand G. Pleuropulmonary aspergilloma: Clinical spectrum and results of surgical treatment. Ann Thorac Surg 1992; 54:1159-64.
174. Kilman JW, Ahn C, Andrews NC, Klassen K. Surgery for pulmonary aspergillosis. J Thorac Cardiovasc Surg 1969; 57:642-7.
175. Chen JC, Chang YL, Luh SP, Lee JM, Lee YC. Surgical treatment for pulmonary aspergilloma: A 28 year experience. Thorax 1997; 52 810-13.
176. Uflacker R, Kaemmerer A, Picon PD, et al. Bronchial artery embolization in the management of hemoptysis: Technical aspects and long-term results. Radiology 1985; 157:637-44.
177. Basich JE, Graves TS, Baz MN, et al. Allergic bronchopulmonary aspergillosis in corticosteroid-dependent asthmatics. J Allergy Clin Immunol 1981; 68:98-102.
178. Mroueh S, Spock A. Allergic bronchopulmonary aspergillosis in patients with cystic fibrosis. Chest 1994; 105:32-6.
179. Wang JL, Patterson R, Rosenberg M, Roberts M, Cooper BJ. Serum IgE and IgG antibody activity against Aspergillus fumigatus as a diagnostic aid in allergic bronchopulmonary aspergillosis. Am Rev Respir Dis 1978; 117:917-27.
180. Cockrill BA, Hales CA. Allergic bronchopulmonary aspergillosis. Annu Rev Med 1999; 50:303-16.
181. Knutsen AP, Slavin RG. In vitro T cell responses in patients with cystic fibrosis and allergic bronchopulmonary aspergillosis. J Lab Clin Med 1989; 113:428-35.
182. Chauhan B, Santiago L, Kirschmann DA, et al. The association of HLA-DR alleles and T cell activation with allergic bronchopulmonary aspergillosis. J Immunol 1997; 159:4072-6.
183. Bosken CH, Myers JL, Greenberger PA, Katzenstein AL. Pathologic features of allergic bronchopulmonary aspergillosis. Am J Surg Pathol 1988; 12:216-22.
184. Rosenberg M, Patterson R, Mintzer R, Cooper BJ, Roberts M, Harris KE. Clinical and immunologic criteria for the diagnosis of allergic bronchopulmonary aspergillosis. Ann Intern Med 1977; 86 405-14.
185. Mintzer RA, Rogers LF, Kruglik GD, Rosenberg M, Neiman HL, Patterson R. The spectrum of radiologic findings in allergic bronchopulmonary aspergillosis. Radiology 1978; 127:301-7.
186. Greenberger PA, Patterson R. Diagnosis and management of allergic bronchopulmonary aspergillosis. Ann Allergy 1986; 56:444-8.
187. Greenberger PA. Immunologic aspects of lung diseases and cystic fibrosis. Jama 1997; 278:1924-30.
188. Patterson R, Greenberger PA, Radin RC, Roberts M. Allergic bronchopulmonary aspergillosis: Staging as an aid to management. Ann Intern Med 1982; 96:286-91.
189. Patterson R, Greenberger PA, Halwig JM, Liotta JL, Roberts M. Allergic bronchopulmonary aspergillosis. Natural history and classification of early disease by serologic and roentgenographic studies. Arch Intern Med 1986; 146:916-18.
190. Rosenberg M, Patterson R, Roberts M, Wang J. The assessment of immunologic and clinical changes occurring during corticosteroid therapy for allergic bronchopulmonary aspergillosis. Am J Med 1978; 64 599-606.
191. Wang JL, Patterson R, Roberts M, Ghory AC. The management of allergic bronchopulmonary aspergillosis. Am Rev Respir Dis 1979; 120 87-92.
192. Capewell S, Chapman BJ, Alexander F, Greening AP, Crompton GK. Corticosteroid treatment and prognosis in pulmonary eosinophilia. Thorax 1989; 44:925-9.
193. Safirstein BH, D'Souza MF, Simon G, Tai EH, Pepys J. Five-year follow-up of allergic bronchopulmonary aspergillosis. Am Rev Respir Dis 1973; 108:450-9.
194. Mikita CP, Mikita JA. Allergic bronchopulmonary aspergillosis. Allergy Asthma Proc 2006; 27:82-4.
195. Hilton AM, Chatterjee SS. Bronchopulmonary aspergillosis-treatment with beclomethasone dipropionate. Postgrad Med J 1975; 51(Suppl. 4 98-103.
196. Seaton A, Seaton RA, Wightman AJ. Management of allergic bronchopulmonary aspergillosis without maintenance oral corticosteroids: a fifteen-year follow-up. Q J Med 1994; 87:529-37.
197. Stevens DA, Schwartz HJ, Lee JY, et al. A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis. N Engl J Med 2000; 342:756-62.
198. Skov M, Main KM, Sillesen IB, Muller J, Koch C, Lanng S. Iatrogenic adrenal insufficiency as a side-effect of combined treatment of itraconazole and budesonide. Eur Respir J 2002; 20:127-33.
199. Hilliard T, Edwards S, Buchdahl R, et al. Voriconazole therapy in children with cystic fibrosis. J Cyst Fibros 2005; 4:215-20.